{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:45Z","timestamp":1792587765370,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ahj.2015.08.023","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T17:24:39Z","timestamp":1442856279000},"page":"1234-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI\u2014rationale and study design of the prospective observational multicenter AVIATOR 2 registry"],"prefix":"10.1016","volume":"170","clinical-trial-number":[{"clinical-trial-number":"nct02362659","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jaya","family":"Chandrasekhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-6629","authenticated-orcid":false,"given":"Ioannis","family":"Mastoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-6220","authenticated-orcid":false,"given":"Mikkel","family":"Schoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ahj.2015.08.023_bb0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2015.08.023_bb0015","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9745","key":"10.1016\/j.ahj.2015.08.023_bb0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"9921","key":"10.1016\/j.ahj.2015.08.023_bb0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2015.08.023_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0035","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ahj.2014.01.005","volume":"167","author":"Fiedler","year":"2014","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ahj.2013.07.028","article-title":"Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial","volume":"166","author":"Sambola","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2015.08.023_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cct.2014.12.002","article-title":"Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS","volume":"40","author":"Lu","year":"2015","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.ahj.2015.08.023_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","article-title":"Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR Registry)","volume":"116","author":"Mennuni","year":"2015","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2015.08.023_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.cir.0000442015.53336.12","article-title":"Executive summary: heart disease and stroke statistics\u20142014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2015.08.023_bb0070","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0075","first-page":"572","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective","volume":"106","author":"Faxon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"23","key":"10.1016\/j.ahj.2015.08.023_bb0080","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ahj.2015.08.023_bb0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ahj.2015.08.023_bb0090","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/eurheartj\/ehr454","article-title":"Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation","volume":"33","author":"Raunso","year":"2012","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ahj.2015.08.023_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/hrt.2007.135657","article-title":"Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis","volume":"94","author":"Andersen","year":"2008","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ahj.2015.08.023_bb0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ahj.2015.08.023_bb0105","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2015.08.023_bb0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ahj.2015.08.023_bb0115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u201creal world\u201d atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"13","key":"10.1016\/j.ahj.2015.08.023_bb0120","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2015.08.023_bb0125","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2015.08.023_bb0130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2015.08.023_bb0135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahj.2015.08.023_bb0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"issue":"9872","key":"10.1016\/j.ahj.2015.08.023_bb0145","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ahj.2015.08.023_bb0150","first-page":"204","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0155","first-page":"563","article-title":"Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry","volume":"26","author":"Rubboli","year":"2014","journal-title":"J Invasive Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2015.08.023_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"issue":"14","key":"10.1016\/j.ahj.2015.08.023_bb0165","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/eurheartj\/ehm186","article-title":"Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?","volume":"28","author":"Nguyen","year":"2007","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.ahj.2015.08.023_bb0175","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ahj.2015.08.023_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0185","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jcin.2012.07.012","article-title":"Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes","volume":"5","author":"Dangas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ahj.2015.08.023_bb0195","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.08.023_bb0200","article-title":"Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives","author":"Alonso-Coello","year":"2014","journal-title":"Health Expect"},{"issue":"8","key":"10.1016\/j.ahj.2015.08.023_bb0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"9683","key":"10.1016\/j.ahj.2015.08.023_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ahj.2015.08.023_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2015.08.023_bb0220","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.ahj.2015.08.023_bb0225","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2015.08.023_bb0230","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ahj.2015.08.023_bb0235","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ahj.2015.08.023_bb0240","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2015.08.023_bb0245","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0250","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ahj.2015.08.023_bb0255","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2015.08.023_bb0260","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.ahj.2015.08.023_bb0265","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.clinthera.2009.11.030","article-title":"Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims","volume":"31","author":"McHorney","year":"2009","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.ahj.2015.08.023_bb0270","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/heartjnl-2014-306754","article-title":"Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction","volume":"101","author":"Shore","year":"2015","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ahj.2015.08.023_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007990802619425","article-title":"The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease","volume":"25","author":"McHorney","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315005967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315005967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:56:35Z","timestamp":1757570195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315005967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0002870315005967"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.08.023","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI\u2014rationale and study design of the prospective observational multicenter AVIATOR 2 registry","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}